Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction(ELASTIC)
NCT07563673 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 210
Last updated 2026-05-08
Summary
This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.
Conditions
- Cerebral Infarction
- Thrombolysis
Interventions
- DRUG
-
Aspirin (Early, 2h)
Aspirin 100mg orally, administered once daily. The first dose is given at 2 hours after rt-PA thrombolysis, conditional on a follow-up CT scan at 2 hours excluding intracranial hemorrhage. Treatment continues for 3 months.
- DRUG
-
Aspirin (Standard, 24h)
Aspirin 100mg orally, administered once daily. The first dose is given at 24 hours after rt-PA thrombolysis, conditional on a follow-up CT scan at 24 hours confirming no intracranial hemorrhage. Treatment continues for 3 months.
Sponsors & Collaborators
-
Beijing Chao Yang Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-01
- Primary Completion
- 2027-09-30
- Completion
- 2027-12-31
Countries
- China
Study Locations
More Related Trials
-
Low-dose Aspirin Therapy in Patients With Ischemic Stroke and Microbleeds
NCT04504864 ·Status: UNKNOWN ·Phase: PHASE4
-
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
NCT00147316 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke
NCT05884502 ·Status: UNKNOWN ·Phase: PHASE4
-
Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke
NCT03661411 ·Status: COMPLETED ·Phase: PHASE4
-
Edoxaban for TIA and Acute Minor Stroke
NCT02221102 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke
NCT01273935 ·Status: COMPLETED
-
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
NCT05401149 ·Status: COMPLETED
-
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
NCT06226805 ·Status: RECRUITING ·Phase: PHASE2
-
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
NCT02239120 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of High and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcome in Patients With AIS
NCT03402204 ·Status: COMPLETED ·Phase: PHASE3
-
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
NCT05395351 ·Status: COMPLETED
-
EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs
NCT05429476 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset
NCT07094763 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Japan Alteplase Clinical Trial Ⅱ:J-ACT Ⅱ)
NCT00412867 ·Status: COMPLETED ·Phase: PHASE4
-
Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke
NCT04142151 ·Status: UNKNOWN ·Phase: NA
-
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
NCT05515393 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke
NCT07163702 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
NCT02930837 ·Status: COMPLETED ·Phase: PHASE3
-
Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance
NCT04071613 ·Status: COMPLETED ·Phase: PHASE2
-
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
NCT05395338 ·Status: COMPLETED
-
The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke
NCT02452502 ·Status: COMPLETED ·Phase: NA
-
Endovascular Acute Stroke Intervention Trial - the EASI Trial
NCT02157532 ·Status: SUSPENDED ·Phase: NA
-
Asia Africa Streptokinase Trial
NCT02150785 ·Status: WITHDRAWN ·Phase: PHASE2